title: Treatment of hidradenitis suppurativa with etanercept injection.
abstract: OBJECTIVE
  To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations.
  
  
  METHODS
  Single-center, randomized, prospective, double-blind, placebo-controlled study.
  
  
  METHODS
  Academic dermatology practice.
  
  
  METHODS
  Twenty patients with active moderate to severe HS who fulfilled all inclusion criteria.
  
  
  METHODS
  Etanercept, 50 mg, or placebo was administered subcutaneously (SC) twice weekly for 12 weeks. After 12 weeks, all patients received open-label etanercept, 50 mg, SC twice weekly for 12 more weeks.
  
  
  METHODS
  Primary end point: physician global assessment of HS as clear or mild at week 12. Secondary end points: patient global assessment and Dermatology Life Quality Index (DLQI).
  
  
  RESULTS
  There was no statistically significant difference among physician global assessment, patient global assessment, and DLQI at 12 or 24 weeks between treatment and placebo groups (P > .05 for all comparisons).
  
  
  CONCLUSIONS
  Etanercept, 50 mg, SC administered twice weekly did not have significant efficacy in the improvement of HS. In light of our negative results, as well as those of previous studies, we suggest that future studies focus on other agents for the treatment of HS. Trial Registration clinicaltrials.gov Identifier: NCT00949546.
authors.affiliation: PharmD, Penn State Hershey, Milton S. Hershey Medical Center, UPC II, 500 University Dr, Ste 4300, Hershey, PA 17033-0850, USA. dadams@psu.edu
authors.forename: David R
authors.initials: DR
authors.lastname: Adams
authors.forename: Jessica A
authors.initials: JA
authors.lastname: Yankura
authors.forename: Anneli C
authors.initials: AC
authors.lastname: Fogelberg
authors.forename: Bryan E
authors.initials: BE
authors.lastname: Anderson
mesh_terms: D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D000068800:Etanercept; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors; D055815:Young Adult
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept